Intriguingly, TCGA and GENIE data revealed that there is a significant co-occurrence of genomic alterations in MGA and TP53 in lung adenocarcinoma patients (Figure 1—figure supplement 1F). The gene discussed is TP53; the disease is lung adenocarcinoma.